Advertisement
U.S. markets open in 6 hours 31 minutes
  • S&P Futures

    4,987.25
    -4.25 (-0.09%)
     
  • Dow Futures

    38,611.00
    -31.00 (-0.08%)
     
  • Nasdaq Futures

    17,577.00
    -30.25 (-0.17%)
     
  • Russell 2000 Futures

    2,013.00
    +2.80 (+0.14%)
     
  • Crude Oil

    78.27
    +0.09 (+0.12%)
     
  • Gold

    2,040.30
    +0.50 (+0.02%)
     
  • Silver

    23.20
    +0.07 (+0.30%)
     
  • EUR/USD

    1.0814
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    4.2750
    0.0000 (0.00%)
     
  • Vix

    15.42
    +0.71 (+4.83%)
     
  • GBP/USD

    1.2631
    +0.0006 (+0.05%)
     
  • USD/JPY

    150.1450
    +0.2190 (+0.15%)
     
  • Bitcoin USD

    51,586.66
    -237.74 (-0.46%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,719.21
    -9.29 (-0.12%)
     
  • Nikkei 225

    38,262.16
    -101.45 (-0.26%)
     

Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg

Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older who have obesity, Bloomberg News reported on Friday, citing a person familiar with the matter.

The company is already conducting a trial of the drug in children as young as 10 years with type 2 diabetes, according to a U.S. government registry.

Lilly's Danish rival Novo Nordisk has also been conducting a late-stage trial of its drug semaglutide, sold under the brand Ozempic, in children as young as 6 years, according to the registry.

Both drugs have seen a surge in demand this year for treatment of diabetes and obesity. Eli Lilly has generated more than $1.5 billion in sales of Mounjaro in the first half of 2023, in just a year after it got approval in the United States.

Eli Lilly did not immediately reply to Reuters' request for comment. (Reporting by Leroy Leo in Bengaluru; Editing by Varun H K)

Advertisement